StreetInsider.com News Articles

Jazz Pharmaceuticals' Ziihera shows 3-year survival data in GEA

Fri, 23 Oct 2026 10:16:02 -0400

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported updated three-year overall survival data from the Phase 3 HERIZON-GEA-01 trial for Ziihera (zanidatamab-hrii) in HER2-positive advanced gastroesophageal adenocarcinoma (GEA), presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.

The second interim and final formal analysis, with a median follow-up of 35.3 months, showed that patients receiving Ziihera plus tislelizumab and chemotherapy achieved a median overall survival (OS) of 27.0 months, compared with 19.6 months for trastuzumab plus chemotherapy, representing a 35% reduction in the risk of death (hazard ratio 0.65; 95% CI: 0.52-0.80). An estimated 39.8% of patients in that

Jazz Pharmaceuticals' Ziihera shows 3-year survival data in GEA

Fri, 23 Oct 2026 10:16:02 -0400

Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Fri, 23 Oct 2026 10:15:00 -0400

Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months

Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy delivered statistically significant and clinically meaningful OS benefit, reducing the risk of death by 24% versus trastuzumab plus chemotherapy

Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Fri, 23 Oct 2026 10:15:00 -0400

Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months

Jazz Pharmaceuticals (JAZZ) PT Lowered to $314 at Morgan Stanley

Wed, 21 Oct 2026 08:22:24 -0400

Morgan Stanley analyst Jeffrey Hung lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $314.00 (from $322.00) while maintaining a Overweight rating.

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026

Mon, 19 Oct 2026 16:15:00 -0400

DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update.

Interested

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026

Mon, 19 Oct 2026 16:15:00 -0400

Interested

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.

While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”